[SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes] - PubMed
7 hours ago
- #Cardiovascular protection
- #Type 2 diabetes
- #GLP-1 receptor agonist
- GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACEs) in at-risk type 2 diabetes (T2D) patients.
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, outperforms pure GLP-1RAs in controlling hyperglycemia, body weight, and cardiovascular risk factors.
- SURPASS CVOT aimed to show non-inferiority of tirzepatide vs. dulaglutide in T2D patients with cardiovascular disease.
- Non-inferiority was confirmed (p = 0.003), but superiority was not achieved (HR 0.92; P = 0.09).
- Secondary outcomes favored tirzepatide, including reduced all-cause deaths after four years (HR 0.84; exploratory analysis).
- SURPASS CVOT is unique for using an active comparator (dulaglutide) instead of placebo.